Olatec Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Olatec Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Olatec Therapeutics: 7 sponsored US clinical trials, 1 recruiting.
Olatec Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gout Attack, with 1 trials.
Upper-quartile sponsor footprint
Olatec Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
NCT05658575
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
NCT04540120
Study of Dapansutrile Capsules in Heart Failure
NCT03534297
Phase 1 Safety and PK Study of OLT1177 Capsules
NCT02134964
Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain
NCT02104050
Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee
NCT01768975
Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects
NCT01636141
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
Therapeutic Areas
What is open in the Olatec Therapeutics pipeline
1 recruiting of 7 indexed (14% open); 5 completed (71%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Gout Attack (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Olatec Therapeutics: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Olatec Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Olatec Therapeutics page
7 registered trials is a research-attention snapshot, not an endorsement of Olatec Therapeutics or any single study.
- 1 of Olatec Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Gout Attack is the condition Olatec Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gout Attack trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Olatec Therapeutics pipeline card: 7 registered trials from official public datasets.Report a data error.